Yu-Pei CHEN

Nasopharyngeal carcinoma (NPC) is highly prevalent in China, accounting for 47% of new cases worldwide each year, posing a significant threat to public health. Over 90% of NPC cases in China are undifferentiated carcinomas, which are highly malignant and prone to metastasizing to multiple organs. Currently, more than 70% of NPC-related deaths are due to distant metastases.

In response to these challenges, Yu-Pei Chen has conducted systematic basic and translational research focused on “mechanisms and intervention strategies of NPC metastasis." He elucidated the critical regulatory role of m6A modification in tumor cells in NPC metastasis, providing new targets for anti-metastasis therapy, identified key immune cell subsets that influence NPC metastatic potential, providing potential targets for modulating the immunosuppressive microenvironment, and proposed the novel metronomic chemotherapy strategy to reduce metastasis risk in NPC patients, thereby improving long-term survival.

As one of the representatives from China, Yu-Pei drafted the Chinese Society of Clinical Oncology (CSCO) and American Society of Clinical Oncology (ASCO) joint guideline of NPC treatment. This is the first time that Chinese scholars and academic organizations have led the development of an international guideline in the medical field. Additionally, he drafted the NPC-focused Seminar for The Lancet, providing a comprehensive introduction to the diagnosis and treatment standards and advancements in NPC to general practitioners worldwide.

In recent years, he has published 20 SCI papers as the first or corresponding author, including in high-impact journals such as Lancet. Three of these papers were selected as ESI Top 1% highly cited papers, and one was selected as an ESI Top 0.1% hot paper. He has been listed in Elsevier's Global Top 2% Scientists for annual scientific impact and currently hold four national invention patents, with three already granted.